Trial reportAnnals of the rheumatic diseases2011
Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression.
Trial report in Annals of the rheumatic diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Ischemia-modified albumin in rheumatic diseases: A systematic review and meta-analysis.Immunity, inflammation and disease · 2024Pooled it
- Pooled it
- A systematic review and meta-analysis of neopterin in rheumatic diseases.Frontiers in immunology · 2023Pooled it
- Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review.Rheumatology international · 2017Pooled it
- [German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm].Zeitschrift fur Rheumatologie · 2012Guideline
- Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?RMD open · 2020Trial
- Joint accumulation and sustained remission in early rheumatoid arthritis.Journal of rheumatic diseases · 2026Article
- Article
- Short- and long-term sustained remission and the role of joint accumulation in early and very early rheumatoid arthritis: a real-world perspective.Journal of rheumatic diseases · 2026Article
- Inclusion of Synovial Tissue-Derived Characteristics in a Nomogram for the Prediction of Treatment Response in Treatment-Naive Rheumatoid Arthritis Patients.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis.Arthritis & rheumatology (Hoboken, N.J.) · 2021Article
- [Management of early rheumatoid arthritis : Interdisciplinary guideline].Zeitschrift fur Rheumatologie · 2020Review
- Evaluating the role of serum sclerostin as an indicator of activity and damage in Egyptian patients with rheumatoid arthritis: university hospital experience.Clinical rheumatology · 2020Article
- Ultrasound remission can predict future good structural outcome in collagen-induced arthritis rats.Scientific reports · 2019Article
- [Improvement of prognosis by timely treatment : Requirement: initial presentation within 6 weeks].Zeitschrift fur Rheumatologie · 2019Review
- The perspective of patients with early rheumatoid arthritis on the journey from symptom onset until referral to a rheumatologist.Rheumatology advances in practice · 2019Article
- Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.Internal medicine (Tokyo, Japan) · 2017Article
- Impact of early diagnosis on functional disability in rheumatoid arthritis.The Korean journal of internal medicine · 2017Observational
- Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.Internal medicine (Tokyo, Japan) · 2017Article
- Long-Term Outcomes in Puerto Ricans with Rheumatoid Arthritis (RA) Receiving Early Treatment with Disease-Modifying Anti-Rheumatic Drugs using the American College of Rheumatology Definition of Early RA.The open rheumatology journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify predictors of clinical remission as well as of no x-ray progression in a cohort of early rheumatoid arthritis (ERA) treated with a tight-control protocol.
methodsA total of 121 consecutive patients with ERA were treated to reach European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR) clinical remission with methotrexate (MTX) for 3 months, then with a combination with anti-tumour necrosis factor if the patient did not achieve a 44-joint Disease Activity Score (DAS44) ≤2.4. At baseline and after 12 months all the patients had hand and foot joint radiographs. Very early rheumatoid arthritis (VERA) was defined as a disease with symptoms of less than 12 weeks.
resultsIn all, 46.3% of the patients reached DAS remission and 24.8% achieved ACR remission. More than 60% of patients reached remission with MTX. Male sex and an erythrocyte sedimentation rate <35 mm/h at onset arose as significant predictors of EULAR remission, while VERA disease was the only predictor of ACR remission. At baseline, 28.1% of the patients were erosive. Multivariate analysis demonstrated that the only independent predictor of erosiveness was 'not having VERA disease'. After 12 months, VERA was the only factor predicting a lack of new erosions.
conclusionsVERA represents the best therapeutic opportunity in clinical practice to achieve a complete remission and to stop the erosive course of rheumatoid arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.